ReviewFrontiers in oncology2014
Is the Evaluation of Quality of Life in NSCLC Trials Important? Are the Results to be Trusted?
Review in Frontiers in oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Fluoxetine as a Potential Therapeutic Agent for Inhibiting Melanoma Brain and Lung Metastasis: Induction of Apoptosis, G0/G1 Cell Cycle Arrest, and Disruption of Autophagy Flux.Journal of Cancer · 2024Article
- Optimal sequencing strategies in the treatment of EGFR mutation-positive non-small cell lung cancer: Clinical benefits and cost-effectiveness.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2020Review
- Effect of early palliative care on quality of life in patients with non-small-cell lung cancer.Current oncology (Toronto, Ont.) · 2018Article
- Role of afatinib in the treatment of advanced lung squamous cell carcinoma.Clinical pharmacology : advances and applications · 2017Review
- New developments in the treatment of advanced squamous cell lung cancer: focus on afatinib.OncoTargets and therapy · 2017Review
- Targeted drugs and Psycho-oncological intervention for breast cancer patients.Journal of negative results in biomedicine · 2016Review
- The treatment of metastatic non-small cell lung cancer in a new era of personalized medicine.Frontiers in oncology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The majority of patients with non-small cell lung cancer present at the time of diagnosis with stage IV metastatic disease and they experience 2 or more disease-related symptoms. These symptoms may have a negative impact on their health-related quality of life (HR QOL). Data has shown many of these patients prefer a therapy to improve their symptoms rather than receive a therapy which slightly prolongs their survival without improving their symptoms. The improvement of disease-related symptoms on a specific drug or regimen augments the significance of prolongation of the progression-free survival or the response rate as well as symptom worsening. The choice of the questionnaires to evaluate patients' reported outcomes and HR QOL benefits and the methods of collecting the data and their interpretations are very important. Only if the data are collected and analyzed properly will they be meaningful and can then be viewed as components that add the total value to a treatment and provide a comprehensive picture of the benefits and risks of a certain anticancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.